Literature DB >> 11741388

The ons and offs of inducible transgenic technology: a review.

A Yamamoto1, R Hen, W T Dauer.   

Abstract

Classical transgenic and gene-targeted mouse mutants are powerful model systems in which to study the pathogenesis of neurodegenerative diseases. However, a number of issues of fundamental importance to neurodegenerative research cannot be addressed using classical techniques. These include identification of the earliest events in disease pathogenesis and a determination of whether a particular pathogenic protein produces a inexorable or a reversible disease process. Both of these issues have profound implications for the rational development of new therapies. To address these questions, genetic techniques that allow pathogenic proteins to be expressed or knocked out with temporal and regional specificity have been developed. We have reviewed these systems, highlighting the tetracycline-regulated system because of its demonstrated utility in mice and its reversibility. These regulatable systems are a new and powerful tool for the neurobiologist and allow one to address a new set of important questions in an in vivo setting.

Entities:  

Mesh:

Year:  2001        PMID: 11741388     DOI: 10.1006/nbdi.2001.0452

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  8 in total

Review 1.  Transgenic RNAi: Accelerating and expanding reverse genetics in mammals.

Authors:  Xu-Gang Xia; Hongxia Zhou; Zuoshang Xu
Journal:  Transgenic Res       Date:  2006-06       Impact factor: 2.788

2.  Design and in vivo characterization of self-inactivating human and non-human lentiviral expression vectors engineered for streptogramin-adjustable transgene expression.

Authors:  Barbara Mitta; Cornelia C Weber; Markus Rimann; Martin Fussenegger
Journal:  Nucleic Acids Res       Date:  2004-07-16       Impact factor: 16.971

3.  Transgenic rat model of neurodegeneration caused by mutation in the TDP gene.

Authors:  Hongxia Zhou; Cao Huang; Han Chen; Dian Wang; Carlisle P Landel; Pedro Yuxing Xia; Robert Bowser; Yong-Jian Liu; Xu Gang Xia
Journal:  PLoS Genet       Date:  2010-03-26       Impact factor: 5.917

4.  Recovery from polyglutamine-induced neurodegeneration in conditional SCA1 transgenic mice.

Authors:  Tao Zu; Lisa A Duvick; Michael D Kaytor; Michael S Berlinger; Huda Y Zoghbi; H Brent Clark; Harry T Orr
Journal:  J Neurosci       Date:  2004-10-06       Impact factor: 6.167

5.  Efficient ROSA26-based conditional and/or inducible transgenesis using RMCE-compatible F1 hybrid mouse embryonic stem cells.

Authors:  Lieven Haenebalcke; Steven Goossens; Michael Naessens; Natascha Kruse; Morvarid Farhang Ghahremani; Sonia Bartunkova; Katharina Haigh; Tim Pieters; Pieterjan Dierickx; Benjamin Drogat; Omar Nyabi; Dagmar Wirth; Jody J Haigh
Journal:  Stem Cell Rev Rep       Date:  2013-12       Impact factor: 5.739

6.  Tetracycline-inducible system for regulation of skeletal muscle-specific gene expression in transgenic mice.

Authors:  Mischala A Grill; Mark A Bales; Amber N Fought; Kristopher C Rosburg; Stephanie J Munger; Parker B Antin
Journal:  Transgenic Res       Date:  2003-02       Impact factor: 2.788

7.  Mutant UBQLN2P497H in motor neurons leads to ALS-like phenotypes and defective autophagy in rats.

Authors:  Tianhong Chen; Bo Huang; Xinglong Shi; Limo Gao; Cao Huang
Journal:  Acta Neuropathol Commun       Date:  2018-11-08       Impact factor: 7.801

8.  Rapid and reversible knockdown of endogenous proteins by peptide-directed lysosomal degradation.

Authors:  Xuelai Fan; Wu Yang Jin; Jie Lu; Jin Wang; Yu Tian Wang
Journal:  Nat Neurosci       Date:  2014-01-26       Impact factor: 24.884

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.